Mary Kay Inc. Partners With Dr. Jack Gilbert to Further Study Skin’s “Microbiome” and the Impact on the Aging Process
7.7.2022 17:30:00 EEST | Business Wire | Press release
Mary Kay Inc., one of the world’s leading skincare research companies, has announced a new partnership with Dr. Jack Gilbert, professor of pediatrics at the University of California San Diego School of Medicine and professor of microbial oceanography at UC San Diego Scripps Institution of Oceanography. Through the partnership, scientists at Mary Kay will work in conjunction with Dr. Gilbert to study one of the most important—but least understood—areas of aging and skin health: the skin Microbiome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005167/en/
Mary Kay Inc. has announced a new partnership with Dr. Jack Gilbert, professor of pediatrics at the University of California San Diego School of Medicine and professor of microbial oceanography at UC San Diego Scripps Institution of Oceanography. Through the partnership, scientists at Mary Kay will work in conjunction with Dr. Gilbert to study one of the most important—but least understood—areas of aging and skin health: the skin Microbiome. (Photo: Mary Kay Inc.)
“Understanding how our normal aging process influences microbiota of the skin may provide startling new discoveries that shape the future in designing cosmetic products,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science at Mary Kay Inc. “We’re thrilled to be partnering with Dr. Gilbert to better understand the impact of the microbiome in overall skin health.”
In 2022, Dr. Gilbert became co-director of the Microbiome and Metagenomics Center at UC San Diego, part of the National Institutes of Health’s $175 million Nutrition for Precision Health program. Combined with Dr. Gilbert’s expertise, scientists at Mary Kay hope to explore how different skin attributes are associated with microbial shifts in women. “There’s a knowledge gap here,” Dr. Gildea added. “We hope to bridge it.”
Previous research has concluded that human skin has its own complex ecosystem of bacteria and other microorganisms that serve as its healthy foundation. Much like what has been found in the gut, human skin—the body’s largest organ—needs these bacteria for optimal function. These bacterial communities also maintain a unique signature based on location, age, gender, and interaction with the environment. There is very limited knowledge of exactly what factors contribute to the highly variable bacterial communities on the skin and their impact on the aging process.
The partnership with Dr. Gilbert is just the latest effort by Mary Kay to reinforce the brand’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005167/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
rhode Launches at Sephora in Europe, Marking Its First Retail Presence Across 19 New Markets30.9.2026 09:30:00 EEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), is available starting today, Wednesday, 30 September, 2026, at Sephora online and in over 500 stores across Europe. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This follows the 2025 rollout with Sephora in the U.S., Canada, and the U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929500812/en/ rhode launches into Sephora across Europe Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode is the No. 1 overall skincare brand in the U.S. by EMV and continues to deliver significant year-over-year growth, according to CreatorIQ.* rhode is now available for con
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superior efficacy compared to deucravacitinib and reinforce the potential for zasocitinib to deliver rapid, durable and consistent skin clearance in a convenient once-daily pill.2-5 “Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals,” said Chinwe Ukomadu, M.D., Ph.D., Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Across our Phase 3 trials, zasocitinib demonstrated superiority versus two distinct oral thera
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 07:16:00 EEST | Press release
Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extensive partner network of digital payment apps, e-commerce platforms and lifestyle service providers, to help expand access to Google AI Plus. Integrated into more than 30 leading digital platform partners, A+ Rewards provides in-app entry points where users
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 07:00:00 EEST | Press release
British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929985154/en/ Signaloid joins CERN openlab: Putting Signaloid's UxHw® Technology to the Test at the World's Largest Particle Collider The collaboration comes as research organisations worldwide are increasingly adopting heterogeneous computing architectures that combine CPUs, GPUs and specialised accelerators to tackle demanding workloads more efficiently. As the High-Luminosity Large Hadron Collider (HiLumi LHC) appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom